

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF  
PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR  
THE QUARTER ENDED 30 SEPTEMBER 2022**

<b>THE GROUP</b>		
	Unaudited Quarter Ended 30 Sep 2022	Unaudited Quarter Ended 30 Sep 2021
	Rs'000	Rs'000
<b>Turnover</b>	723,874	657,538
Earnings Before Interests, Taxation, Depreciation and Amortisation (EBITDA)	162,938	173,551
Depreciation and amortisation	(40,158)	(32,032)
<b>Earnings Before Interests and Taxation (EBIT)</b>	<b>122,780</b>	<b>141,519</b>
Net finance cost	(13,678)	(14,425)
<b>Profit before taxation</b>	<b>109,102</b>	<b>127,094</b>
Taxation	(18,646)	(22,243)
<b>Profit after tax</b>	<b>90,456</b>	<b>104,851</b>
<b>Attributable to:</b>		
Equity holders	90,456	104,851
<b>Earnings per share</b>		
Earnings attributable to equity holders	90,456	104,851
Number of shares in issue ('000)	569,941	569,941
<b>Earnings per share (Rs/Cs)</b>	<b>0.16</b>	<b>0.18</b>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS  
OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2022**

<b>THE GROUP</b>		
	Unaudited As at 30 Sep 2022	Audited As at 30 June 2022
	Rs'000	Rs'000
<b>ASSETS</b>		
Non-current assets	<b>2,485,970</b>	2,453,081
Current assets	<b>707,121</b>	843,057
<b>TOTAL ASSETS</b>	<b>3,193,091</b>	3,296,138
<b>EQUITY AND LIABILITIES</b>		
Equity attributable to:		
Equity holders	<b>1,151,978</b>	1,061,522
<b>TOTAL EQUITY</b>	<b>1,151,978</b>	1,061,522
Non-current liabilities	<b>1,198,886</b>	1,250,959
Current liabilities	<b>842,227</b>	983,657
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3,193,091</b>	3,296,138

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES  
IN EQUITY FOR THE QUARTER ENDED 30 SEPTEMBER 2022**

<b>Attributable to equity holders</b>				
<b>THE GROUP</b>	Issued Capital	Revaluation reserve	Retained Earnings	Total Equity
	Rs'000	Rs'000	Rs'000	Rs'000
At 1 July 2021	289,801	265,495	269,900	<b>825,196</b>
Profit for the period	-	-	104,851	<b>104,851</b>
<b>At 30 Sep 2021</b>	<b>289,801</b>	<b>265,454</b>	<b>374,751</b>	<b>930,047</b>
At 1 July 2022	289,801	345,241	426,480	<b>1,061,522</b>
Profit for the year	-	-	90,456	<b>90,456</b>
<b>At 30 Sep 2022</b>	<b>289,801</b>	<b>345,241</b>	<b>516,936</b>	<b>1,151,978</b>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS  
OF CASH FLOWS FOR THE QUARTER  
ENDED 30 SEPTEMBER 2022**

<b>THE GROUP</b>		
	Unaudited Quarter Ended 30 Sep 2022	Unaudited Quarter Ended 30 Sep 2021
	Rs'000	Rs'000
Net Cash flows from operating activities	154,791	131,897
Net Cash flows used in investing activities	(84,144)	(33,289)
Net Cash flows used in financing activities	(244,966)	(170,779)
<b>Increase in cash and cash equivalent</b>	<b>(174,319)</b>	(72,171)
<b>MOVEMENT IN CASH AND CASH EQUIVALENT</b>		
At the beginning of the year	<b>398,220</b>	234,852
Movement during the year	<b>(174,319)</b>	(72,171)
<b>At the end of the year</b>	<b>223,901</b>	162,681

**NOTES**

The abridged financial statements for the quarter ended 30 September 2022 are unaudited and have been prepared using the same accounting policies as in the audited financial statements for the year ended 30 June 2022.

The above results is a consolidated view of the operations of C-Care Darné, C-Care Wellkin and C-Lab including C-Care North Ltd and Centre de Radiotherapie de l'Océan Indien Ltd, wholly owned subsidiaries of C-Care (Mauritius) Ltd.

Despite decrease in Covid related activities, the Group generated good results for the quarter as normal activities picked up.

The Board of Directors of C-Care (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this report.

By Order of the Board

**CIEL Corporate Services Ltd**  
**Company Secretary**

Date: 11 November 2022

BRN: C07002054

This report is pursuant to Rule 17 of the Development & Enterprise Market and Securities Act 2005.

Copies of the Unaudited Condensed Financial Statements are available to the public free of charge at the Company's registered office: 5th Floor, Ebène Skies, rue de l'Institut, Ebène.  
The statement of direct and indirect interests of insiders pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007 is available free of charge at the registered office of the Company.



**C-CARE (MAURITIUS) LTD**

---

## **NOTICE**

### **UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE QUARTER ENDED 30 SEPTEMBER 2022**

The Board of Directors of C-Care (Mauritius) Ltd (the "Company") wishes to inform its shareholders and the public in general that the Unaudited Condensed Consolidated Financial Statements of the Company and its Subsidiaries for the quarter ended 30 September 2022 have been approved on 11 November 2022.

The Unaudited Condensed Consolidated Financial Statements of the Company and its Subsidiaries will be published on the website of the Company on <https://c-care.com/mu/investors-corner/> and copies of same are available to the public free of charge at the registered office of the Company at 5<sup>th</sup> Floor, Ebène Skies, Rue de l'Institut, Ebène.

By Order of the Board

**CIEL Corporate Services Ltd**  
Company Secretary

11 November 2022

This Notice is given pursuant to DEM Rule 17.3 and the Securities Act 2005.

The Board of Directors of C-Care (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this Notice.

**BRN: C07002054**